Lynx1 Capital Management LP

CIK 1910456 · View on SEC EDGAR ↗

Portfolio value QoQ: +36.8% 13F does not disclose cash

Top 10 holdings weight98.82%

Top 25 holdings weight99.99%

Positions above 1%6

Effective number of positions4.0

Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)

Turnover Q2 2026: 11.22% Est. buys $102,601,678 · sells $84,029,041

Median holding: 3.0 quarters Tracked Q1 2025–Q2 2026 · 67.5% still held

New positions6

Increased6

Decreased7

Closed2

Portfolio value $865.5M #2,796 of 9,339 by 13F value · top 29.9%

Positions 27

As of June 30, 2026 Data as of Q2 2026

Performance vs S&P 500

Tracked Q1 2025–Q2 2026 +208.9%

S&P 500 total return (same window) +37.0%

Excess return +171.9%

Annualized: +146.6% · S&P 500: +28.7%

Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.

Priceable coverage: 100.0% · Options excluded: 0.0%

Sector breakdown

Healthcare 100.0%

Full portfolio 27 positions

					Streak
GHRS GH Research PLC - Ordinary Shares	$356,517,181	41.19%	13,263,288	$205,185,352	Up ×6
CGEM Cullinan Therapeutics, Inc. - Common Stock	$163,225,335	18.86%	8,963,500	$35,854,000
STOK Stoke Therapeutics, Inc. - Common Stock	$132,136,579	15.27%	4,038,404	$-22,968,614	Down ×2
AGIO Agios Pharmaceuticals, Inc. - Common Stock	$126,505,652	14.62%	3,408,937	$38,156,307	Up ×2
CCCC C4 Therapeutics, Inc. - Common Stock	$34,215,647	3.95%	7,326,691	$15,808,535	Up ×1
KRRO Korro Bio, Inc. - Common Stock	$20,274,741	2.34%	1,538,296	$2,861,230
TCRX TScan Therapeutics, Inc. - Common Stock	$7,859,567	0.91%	8,019,148	$-239,772
DTIL Precision BioSciences, Inc. - Common Stock	$7,470,663	0.86%	950,466	$2,052,541	Down ×3
NEUP Neuphoria Therapeutics Inc. - Common Stock	$3,825,183	0.44%	875,328	$262,598
PASG Passage Bio, Inc. - Common Stock	$3,287,942	0.38%	673,759	$-1,608,134	Up ×1
CGON CG Oncology, Inc. - Common stock	$2,230,331	0.26%	31,391	$92,252	Down ×1
PLRX Pliant Therapeutics, Inc. - Common Stock	$2,049,800	0.24%	1,798,070		Up ×1
TRDA Entrada Therapeutics, Inc. - Common Stock	$1,314,540	0.15%	178,606	$-1,356,975	Down ×1
VYNE VYNE Therapeutics Inc. - Common Stock	$1,059,795	0.12%	1,628,700	$86,647
PRQR ProQR Therapeutics N.V. - Ordinary Shares	$969,828	0.11%	521,413	$858,881	Up ×1
TRAW Traws Pharma, Inc. - Common Stock	$471,801	0.05%	559,470	$444,208	Up ×1
FHTX Foghorn Therapeutics Inc. - Common Stock	$300,549	0.03%	61,588		Up ×1
DNLI Denali Therapeutics Inc. - Common Stock	$299,844	0.03%	11,658	$-35,801,974	Down ×1
XNCR Xencor, Inc. - Common Stock	$292,923	0.03%	18,194	$-6,176,037	Down ×2
ABSI Absci Corporation - Common Stock	$246,230	0.03%	21,245	$182,495
HOWL Werewolf Therapeutics, Inc. - Common Stock	$236,737	0.03%	657,786	$-310,936
IMTX Immatics N.V. - Ordinary Shares	$235,381	0.03%	23,236	$-1,899,633	Down ×2
AVTX Avalo Therapeutics, Inc. - Common Stock	$186,648	0.02%	10,100		Up ×1
BOLT Bolt Biotherapeutics, Inc. - Common Stock	$118,580	0.01%	30,800	$-5,852
NUVB Nuvation Bio Inc. Class A Common Stock	$91,045	0.01%	16,029		Up ×1
EPRX Eupraxia Pharmaceuticals Inc. - Common Stock	$66,100	0.01%	10,000		Up ×1
IKT Inhibikase Therapeutics, Inc. - Common Stock	$40,600	0.00%	20,000		Up ×1
No matches

Conviction holdings

Positions increased for 3+ consecutive quarters.

Share counts are as reported in 13F filings (not split-adjusted)

Security	Value	% of portfolio	Streak
GHRS	$356,517,181	41.19%	up ×6

Biggest new bets

New positions opened this quarter, largest first.

Security	Value	Shares	% of portfolio
PLRX	$2,049,800	1,798,070	0.24%
FHTX	$300,549	61,588	0.03%
AVTX	$186,648	10,100	0.02%
NUVB	$91,045	16,029	0.01%
EPRX	$66,100	10,000	0.01%
IKT	$40,600	20,000	0.00%

Top movers (QoQ)

Security	Action	Shares Δ	Value Δ
GHRS	Bought more	+2.5M	+$205.2M
AGIO	Bought more	+797K	+$38.2M
CGEM	Price move only	+0	+$35.9M
STOK	Trimmed	-725K	-$23.0M
CCCC	Bought more	+328K	+$15.8M
KRRO	Price move only	+0	+$2.9M
DTIL	Trimmed	-35K	+$2.1M
PASG	Bought more	+50K	-$1.6M
TRDA	Trimmed	-33K	-$1.4M
HOWL	Price move only	+0	-$311K

5 positions hidden — reported move looks larger than the position itself (data completeness check)

Exited positions

Includes corporate events (mergers, delistings) — not all exits are sells

Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.

Security	Quarter	Shares before	Value before	Price since exit
MRUS	Dec. 31, 2025	1,534,141	$144,439,375	No longer tracked
PTGX	Dec. 31, 2025	700,014	$46,501,930	58.5%
ADCT	Dec. 31, 2025	1,325,848	$5,303,392	-59.2%
UPB	Sept. 30, 2025	219,247	$2,407,332	-85.4%
DSGN	June 30, 2026	119,516	$1,271,650	-29.2%
IBIO	Dec. 31, 2025	1,055,897	$874,072	-62.8%
ARWR	March 31, 2026	12,043	$799,535	-7.5%
ALLO	Dec. 31, 2025	546,119	$677,188	-8.8%
NEUP	Sept. 30, 2025	45,806	$325,223	-70.8%
MPLT	March 31, 2026	13,477	$236,724	-60.8%
ASMB	Sept. 30, 2025	10,366	$187,832	-22.5%
GBIO	March 31, 2026	25,000	$142,000	No longer tracked
IBIO	June 30, 2026	68,076	$129,344	-59.0%
APLT	March 31, 2026	410,500	$41,050	No longer tracked

Person profile: Lynx1 Capital Management LP